Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Indian Journal of Surgical Oncology
Erschienen in: Indian Journal of Surgical Oncology 1/2021

16.03.2021 | Original Article

Molecular Oncology in Management of Colorectal Cancer

verfasst von: Ramraj Nagendra Gupta Vemala, Sanjeev Vasudev Katti, Bhawna Sirohi, Divya Manikandan, Govind Nandakumar

Erschienen in: Indian Journal of Surgical Oncology | Sonderheft 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Colorectal cancers are the third most common cancers in the world. Management of both primary and metastatic colorectal cancers has evolved over the last couple of decades. Extensive research in molecular oncology has helped us understand and identify these complex intricacies in colorectal cancer biology and disease progression. These advances coupled with improved knowledge on various mutations have helped develop targeted chemotherapeutics and has allowed planning an effective treatment regimen in this era of immunotherapy with precision. The diverse chemotherapeutic and biological agents at our disposal can make decision making a very complex process. Molecular profile, including CIN, RAS, BRAF mutations, microsatellite instability, ctDNA, and consensus molecular subtypes, are some of the important factors which are to be considered while planning an individualized treatment regimen. This article summarizes the current status of molecular oncology in the management of colorectal cancer and should serve as a practical guide for the clinical team.
Literatur
1.
2.
3.
Ferlay J, Dikshit R, Elser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2013) GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase no. 11 [internet]. International Agency for Research on Cancer, Lyon Available from: http://​globocan.​iarc.​fr/​Pages/​burden_​sel.​aspx. Accessed 25 Aug 2014
4.
NCRP (2013) Three-year report of the population based cancer registries- 2009-2011. National cancer registry programme, Indian council of medical research (ICMR), Bangalore, India, p 2013
5.
Rabeneck L, Davila JA, El-Serag HB (2003) Is there a true “shift” to the right colon in the incidence of colorectal cancer? Am J Gastroenterol 98:1400–1409PubMed
6.
Chang L, Chang M, Chang HM, Chang F (2017) Expending role of microsatellite instability in diagnosis and treatment of colorectal cancers. J Gastrointest Cancer 48(4):305–313PubMedPubMedCentral
7.
Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC (1994) A prospective study of family history and the risk of colorectal cancer. N Engl J Med 331:1669–1674PubMed
8.
Zhang X, Li J (2013) Era of universal testing of microsatellite instability in colorectal cancer. World J Gastrointest Oncol 5(2):12–19PubMedPubMedCentral
9.
Vasen HF, Watson P, Mecklin JP et al (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116(6):1453–1456PubMed
10.
Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J (2017) Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer 17(2):79–92PubMed
11.
O’Brien MJ, Yang S, Clebanoff JL, Mulcahy E, Farraye FA, Amorosino M et al (2004) Hyperplastic (serrated) polyps of the colorectum: relationship of CpG island methylator phenotype and K-ras mutation to location and histologic subtype. Am J Surg Pathol 28(4):423–434. https://​doi.​org/​10.​1097/​00000478-200404000-00001
12.
Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61(5):759–767PubMed
13.
Sjöblom T, Jones S, Wood LD et al (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314(5797):268–274PubMed
14.
Pino MS, Chung DC (2010) The chromosomal instability pathway in colon cancer. Gastroenterology 138(6):2059–2072PubMed
15.
Grady WM (2004) Genomic instability and colon cancer. Cancer Metastasis Rev 23(1/2):11–27PubMed
16.
17.
Mcgranahan N, Burrell RA, Endesfelder D, Novelli MR, Swanton C (2012) Cancer chromosomal instability: therapeutic and diagnostic challenges. EMBO Rep 13(6):528–538PubMedPubMedCentral
18.
Baran B, Ozupek NM, Tetik NY, Acar E, Bekcioglu O, Baskin Y (2018) Difference between left-sided and right-sided colorectal cancer: a focused review of literature. Gastroenterol Res 11(4):264–273
19.
Swanton C, Marani M, Pardo O, Warne PH, Kelly G, Sahai E et al (2007) Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 11(6):498–512PubMed
20.
Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M (1993) Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363(6429):558–561PubMed
21.
Gryfe R, Kim H, Hsieh ET et al (2000) Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342(2):69–77PubMed
22.
Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan R, Zborowska E, Kinzler K, Vogelstein B, (1995) Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 268(5215):1336–1338
23.
Gupta R, Sinha S, Paul RN (2018) The impact of microsatellite stability status in colorectal cancer. Curr Probl Cancer 42(6):548–559PubMed
24.
Peluso G, Incollingo P, Calogero A, Tammaro V, Rupealta N, Chiacchio G et al (2017) Current tissue molecular markers in colorectal cancer: a literature review. Biomed Res Int 2017:1–8
25.
Inamura K (2018) Colorectal cancers: an update on their molecular pathology. Cancers. 10(1):26PubMedCentral
26.
Bever KM, Le DT (2017) An expanding role for immunotherapy in colorectal cancer. J Natl Compr Cancer Netw 15:401–410
27.
Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW et al (1998) A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer [Internet]. Cancer Res US National Library of Medicine 58(22):5248-57
28.
Kim C-G, Ahn JB, Jung M, Beom SH, Kim JH, Heo SJ et al (2016) Patterns of recurrence by microsatellite instability in colorectal cancer. J Clin Oncol 34(4_suppl):501
29.
Kim CG, Ahn JB, Jung M, Beom SH, Kim C, Kim JH, Heo SJ, Park HS, Kim JH, Kim NK, Min BS, Kim H, Koom WS, Shin SJ (2016) Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers. Br J Cancer 115(1):25–33PubMedPubMedCentral
30.
Copija A, Waniczek D, Witkoś A, Walkiewicz K, Nowakowska-Zajdel E (2017) Clinical significance and prognostic relevance of microsatellite instability in sporadic colorectal cancer patients. Int J Mol Sci 18(1):107PubMedCentral
31.
Kang J, Lee HW, Kim I-K, Kim NK, Sohn S-K, Lee KY (2010) Clinical implications of microsatellite instability in t1 colorectal cancer. Yonsei Med J 56(1):175
32.
Kawakami H, Zaanan A, Sinicrope FA (2015) Microsatellite instability testing and its role in the management of colorectal cancer. Curr Treat Options in Oncol 16(7)
33.
34.
35.
Lee DT, Uram J, Wang H, Bartlett BR, Kemberling H, Eyring AD (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 373(20):1979
36.
Kalyan A, Kircher S, Shah H, Mulcahy M, Benson A (2018) Updates on immunotherapy for colorectal cancer. J Gastrointest Oncol 9(1):160–169PubMedPubMedCentral
37.
Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, Koh H, Simms L, Barker M, Leggett B, Levine J, Kim M, French AJ, Thibodeau SN, Jass J, Haile R, Laird PW (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38(7):787–793PubMed
38.
Fennell LJ, Jamieson S, McKeone D, Corish T, Rohdmann M, Furner T et al (2018) MLH1–93 G/a polymorphism is associated with MLH1 promoter methylation and protein loss in dysplastic sessile serrated adenomas with BRAFV600E mutation. BMC Cancer 18(1):35PubMedPubMedCentral
39.
Bettington ML, Walker NI, Rosty C, Brown IS, Clouston AD, McKeone DM et al (2015) A clinicopathological and molecular analysis of 200 traditional serrated adenomas. Mod Pathol 28(3):414–427PubMed
40.
Hashimoto T, Yamashita S, Yoshida H, Taniguchi H, Ushijima T, Yamada T, Saito Y, Ochiai A, Sekine S, Hiraoka N (2017) WNT pathway gene mutations are associated with the presence of dysplasia in colorectal sessile serrated adenoma/polyps. Am J Surg Pathol 41(9):1188–1197PubMed
41.
Yan HHN, Lai JCW, Ho SL, Leung WK, Law WL, Lee JFY, Chan AKW, Tsui WY, Chan ASY, Lee BCH, Yue SSK, Man AHY, Clevers H, Yuen ST, Leung SY (2017) RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation. Gut. 66(9):1645–1656PubMed
42.
Murcia O, Juárez M, Rodríguez-Soler M, Hernández-Illán E, Giner-Calabuig M, Alustiza M, Egoavil C, Castillejo A, Alenda C, Barberá V, Mangas-Sanjuan C, Yuste A, Bujanda L, Clofent J, Andreu M, Castells A, Llor X, Zapater P, Jover R (2018) Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: prognostic implications and response to chemotherapy. PLoS One 13(9):e0203051PubMedPubMedCentral
43.
Yaeger R, Cercek A, Chou JF, Sylvester BE, Kemeny NE, Hechtman JF, Ladanyi M, Rosen N, Weiser MR, Capanu M, Solit DB, D’Angelica MI, Vakiani E, Saltz LB (2014) BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer. 120(15):2316–2324PubMed
44.
The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern - PubMed [Internet]. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​30035653/​. Accessed 18 Nov 2020
45.
Ursem C, Atreya CE, Van Loon K (2018) Emerging treatment options for BRAF-mutant colorectal cancer. Gastrointest Cancer 8:13–23PubMedPubMedCentral
46.
Murcia O, Juárez M, Hernández-Illán E, Egoavil C, Giner-Calabuig M, Rodríguez-Soler M, Jover R (2016) Serrated colorectal cancer: molecular classification, prognosis, and response to chemotherapy. World J Gastroenterol 22(13):3516–3530PubMedPubMedCentral
47.
Rafal S, Andrzej P, Agnieszka S et al (2010) Colorectal cancer in the course of familial adenomatous polyposis syndrome (“de novo” pathogenic mutation of APC gene): case report, review of literature and genetic commentary. Arch Med Sci 6(2):283–287
48.
49.
50.
Aihara H, Kumar N, Thompson CC (2014) Diagnosis, surveillance, and treatment strategies for familial adenomatous polyposis. Eur J Gastroenterol Hepatol 26(3):255–262PubMedPubMedCentral
51.
Hernegger GS, Moore HG, Guillem JG (2002) Attenuated familial adenomatous polyposis: an evolving and poorly understood entity. Dis Colon Rectum 45(1):127–134 discussion 134-6PubMed
52.
Burt RW, Leppert MF, Slattery SL et al (2004) Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis. Gastroenterology 127(2):444–451PubMed
53.
54.
Nugent KP, Phillips RKS (1992) Rectal cancer risk in older patients with familial adenomatous polyposis and an ileorectal anastomosis: a cause for concern. Br J Surg 79(11):1204–1206PubMed
55.
56.
57.
Lynch H, Lynch P, Lanspa S, Snyder C, Lynch J, Boland C (2009) Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 76(1):1–18PubMedPubMedCentral
58.
59.
Grindedal EM, Renkonen-Sinisalo L, Vasen H, Evans G, Sala P, Blanco I, Gronwald J, Apold J, Eccles DM, Sánchez AA, Sampson J, Järvinen HJ, Bertario L, Crawford GC, Stormorken AT, Maehle L, Moller P (2009) Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds. J Med Genet 47(2):99–102. https://​doi.​org/​10.​1136/​jmg.​2009.​068130CrossRefPubMed
60.
Lin-Hurtubise KM, Ishihara K, McLaughlin K, Morte D, Sheffler R (2015) Lynch syndrome: expanded tumor spectrum, universal screening and multimodal treatment strategies for colon cancer. Transl Gastrointest Cancer 4(5)
61.
62.
63.
64.
HFA V, JCH H (2007) An overview of the Lynch syndrome (hereditary non-polyposis colorectal cancer). Hereditary Color Cancer 271–299
65.
66.
Umar A, Boland CR, Terdiman JP, Syngal S, Chapelle A, Ruschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HFA, Hawk ET, Barrett JC, Freedman AN, Srivastava S (2004) Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261–268PubMed
67.
Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ (2014) Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov 13(11):828–851PubMedPubMedCentral
68.
Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M (2013) Panitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023–1034PubMed
69.
Cutsem EV, Lenz H-J, Köhne C-H, Heinemann V, Tejpar S, Melezínek I et al (2015) Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 33(7):692–700PubMed
70.
Cutsem EV, Cervantes A, Nordlinger B, Arnold D (2014) Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(suppl 3):iii1–iii9PubMed
71.
Kemeny NE, Chou JF, Capanu M, Gewirtz AN, Cercek A, Kingham TP et al (2013) Influence of KRAS mutation on recurrence patterns in patients undergoing hepatic resection of colorectal metastases. J Clin Oncol 31(4_suppl):398
72.
Karagkounis G, Torbenson MS, Daniel HD, Azad NS, Diaz LA, Donehower RC et al (2013) Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer 119(23):4137–4144PubMed
73.
74.
75.
Tran B, Kopetz S, Tie J, Gibbs P, Jiang Z, Lieu C et al (2011) Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 117(20):4623–4632PubMed
76.
Yaeger R, Cercek A, Chou J, Sylvester B, Kemeny N, Hechtman J et al (2014) BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer. 120(15):2316–2324PubMed
77.
Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P et al (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26(35):5705–5712PubMed
78.
Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlomagno C, Allegrini G, Chiara S, D’Amico M, Granetto C, Cazzaniga M, Boni L, Fontanini G, Falcone A (2015) FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 16(13):1306–1315PubMed
79.
Tie J, Kinde I, Wang Y, Wong HL, Roebert J, Christie M et al (2015) Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol
80.
Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I et al (2016) Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 8(346)
81.
Thierry AR, Mouliere F, Messaoudi SE, Mollevi C, Lopez-Crapez E, Rolet F et al (2014) Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med 20(4):430–435PubMed
82.
Wang F, Bai L, Liu T-S, Yu Y-Y, He M-M, Liu K-Y et al (2015) Right- and left-sided colorectal cancers respond differently to cetuximab. Chin J Cancer 34(3)
83.
Boeckx N, Koukakis R, Beeck KOD, Rolfo C, Camp GV, Siena S et al (2017) Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Ann Oncol 28(8):1862–1868PubMedPubMedCentral
84.
Ishihara S, Nishikawa T, Tanaka T, Tanaka J, Kiyomatsu T, Kawai K, Hata K, Nozawa H, Kanazawa T, Kazama S, Yamaguchi H, Sunami E, Kitayama J, Hashiguchi Y, Sugihara K, Watanabe T (2014) Prognostic impact of tumor location in stage IV colon cancer: a propensity score analysis in a multicenter study. Int J Surg 12(9):925–930PubMed
85.
Wang Z, Wang X, Zhang Z, Wang X, Chen M, Lu L, Zhu W, Zhang J, Jia H, Chen J (2019) Association between primary tumor location and prognostic survival in synchronous colorectal liver metastases after surgical treatment: a retrospective analysis of SEER data. J Cancer 10(7):1593–1600PubMedPubMedCentral
86.
Punt CJ, Koopman M, Vermeulen L (2017) From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol 14:235–246PubMed
87.
Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, de Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S (2015) The consensus molecular subtypes of colorectal cancer. Nat Med 21:1350–1356PubMedPubMedCentral
88.
Lenz HJ, Ou FS, Venook AP, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer RJ, Bertagnolli MM, Blanke CD, Zemla T, Qu X, Wirapati P, Tejpar S, Innocenti F, Kabbarah O (2019) Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB/SWOG 80405 (Alliance). J Clin Oncol 37(22):1876–1885PubMedPubMedCentral
89.
Takegawa N, Yonesaka K (2017) HER2 as an emerging oncotarget for colorectal cancer treatment after failure of anti-epidermal growth factor receptor therapy. Clin Colorectal Cancer 16(4):247–251PubMed
90.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235(4785):177–182PubMed
91.
Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Säve-Söderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992;10(7):1049–1056
92.
Gravalos C, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19(9):1523–1529PubMed
93.
Begnami MD, Fukuda E, Fregnani JHTG, Nonogaki S, Montagnini AL, da Costa WL et al (2011) Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol 29(22):3030–3036PubMed
94.
Ross JS, Fakih M, Ali SM, Elvin JA, Schrock AB, Suh J et al (2018) Targeting HER2 in colorectal cancer: the landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer 124(7):1358–1373PubMed
95.
Yaeger R, Chatila WK, Lipsyc MD, Hechtman JF, Cercek A, Sanchez-Vega F et al (2018) Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. Cancer Cell 33(1):125–136.e3PubMedPubMedCentral
96.
Richman SD, Southward K, Chambers P, Cross D, Barrett J, Hemmings G, Taylor M, Wood H, Hutchins G, Foster JM, Oumie A, Spink KG, Brown SR, Jones M, Kerr D, Handley K, Gray R, Seymour M, Quirke P (2016) HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol 238(4):562–570PubMedPubMedCentral
97.
Ingold Heppner B, Behrens H-M, Balschun K, Haag J, Krüger S, Becker T, Röcken C (2014) HER2/neu testing in primary colorectal carcinoma. Br J Cancer 111(10):1977–1984PubMedPubMedCentral
98.
Kruszewski WJ, Rzepko R, Ciesielski M, Szefel J, Zieliński J, Szajewski M, Jasiński W, Kawecki K, Wojtacki J (2010) Expression of HER2 in colorectal cancer does not correlate with prognosis. Dis Markers 29(5):207–212PubMed
99.
Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russolillo N, Muratore A, Massucco P, Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, Risio M, Capussotti L, Gambacorta M, Siena S, Medico E, Sapino A, Marsoni S, Comoglio PM, Bardelli A, Trusolino L (2011) A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 1(6):508–523PubMed
100.
Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J et al (2011) Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 3(99):99ra86PubMedPubMedCentral
101.
Siena S, Trusolino L, Martino C, Bencardino K, Lonardi S, Zagonel V et al (2017) Abstract CT005: final results of the HERACLES trial in HER2-amplified colorectal cancer. Cancer Res 77:CT005–CT005
102.
Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A et al (2019) Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 20(4):518–530PubMedPubMedCentral
103.
Metadaten
Titel
Molecular Oncology in Management of Colorectal Cancer
verfasst von
Ramraj Nagendra Gupta Vemala
Sanjeev Vasudev Katti
Bhawna Sirohi
Divya Manikandan
Govind Nandakumar
Publikationsdatum
16.03.2021
Verlag
Springer India
Erschienen in
Indian Journal of Surgical Oncology / Ausgabe Sonderheft 1/2021
Print ISSN: 0975-7651
Elektronische ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-021-01289-6

Weitere Artikel der Sonderheft 1/2021

Indian Journal of Surgical Oncology 1/2021 Zur Ausgabe

Original Article

Analysis of SET and MYND Domain-Containing Protein 3 (SMYD3) Expression in Gallbladder Cancer: a Pilot Study

Original Article

Genetic Counseling Clinic at AIIMS (New Delhi)

Case Report

Functional Malignant Retroperitoneal Paraganglioma with Liver Metastasis: a Rare Case Report

Case Report

Bilateral Primary Ovarian Clear Cell Carcinoma in an Iranian Woman: a Case Report

Case Report

A Rare Case of Epithelioid Myofibroblastoma of Breast Mimicking Lobular Carcinoma on Trucut Biopsy: a Diagnostic Pitfall and Literature Review

Case Report

Dural Metastasis from Breast Carcinoma Mimicking Sub-acute Subdural Hematoma: a Case Report

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.